Moderna on Wednesday said Blackstone’s sciences arm would offer $750 million to help fund development of its flu vaccines, bolstering the company’s efforts to advance multiple vaccines in the face of a steep decline in sales of its COVID-19 shots.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
